Interpreting Patient-Reported Outcome Scores: Pediatric Inflammatory Bowel Disease as a Use Case


dc.contributor.authorSchuchard J
dc.contributor.authorCarle AC
dc.contributor.authorKappelman MD
dc.contributor.authorTucker CA
dc.contributor.authorForrest CB
dc.contributor.otherChildren's Hospital of Philadelphia
dc.contributor.otherCincinnati Children's Hospital Medical Center
dc.contributor.otherUniversity of Cincinnati
dc.contributor.otherUniversity of North Carolina at Chapel Hill
dc.contributor.otherTemple University
dc.date.accessioned2026-06-09T15:42:09Z
dc.date.created2022-12
dc.date.issued2022-12
dc.description.abstract**Objective:** To demonstrate how to interpret Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric patient-reported outcome measure (PROM) scores for patients with pediatric inflammatory bowel disease (IBD). **Methods:** Using data from a prospective cohort study of patients ages 8 to 23 years with IBD (n = 1049), we established disease-specific percentiles and computed the minimal clinically important difference (MCID) change score for 6 pediatric PROMs. We applied these results, general population percentiles, and the reliable change index to interpret PROM scores in a clinical trial sample of patients ages 8 to 20 years with IBD (n = 294) in which PROMIS PROMs were obtained at baseline and 3 months later. **Results:** Application of general population percentiles showed that the clinical trial sample at baseline had moderately worse self-reported health than the general population (22% of patients at or above the 95th percentile on Fatigue; 21% on Pain Interference). IBD-specific percentiles showed that the sample was somewhat worse than the reference IBD sample (8% of patients at or above the 95th percentile on Fatigue; 11% on Pain Interference). Application of the MCID threshold indicated that among the subgroup of patients that improved by 15 or more on the short Pediatric Crohn's Disease Activity Index (n = 38), 45% also improved on IBD Symptoms, 47% for Fatigue, and 65% for Pain Interference. **Conclusion:** This study established IBD-specific percentiles for 6 pediatric PROMIS measures and demonstrated the application of percentiles and other methods for interpreting PROM scores.
dc.identifier.citationSchuchard J, Carle AC, Kappelman MD, Tucker, Carole A., Forrest CB. 2022. "Interpreting Patient-Reported Outcome Scores: Pediatric inflammatory bowel disease as a use case." _Academic Pediatrics_. 22, (8), 1520-1528.<br> DOI:[10.1016/j.acap.2021.12.029](https://doi.org/10.1016/j.acap.2021.12.029)
dc.identifier.doi10.1016/j.acap.2021.12.029
dc.identifier.urihttps://hdl.handle.net/20.500.14642/1674
dc.identifier.urihttps://doi.org/10.24373/pdsp-730
dc.publisherAcademic Pediatrics
dc.relation.urihttps://pubmed.ncbi.nlm.nih.gov/34995822/
dc.rightsCopyright © 2022 Academic Pediatric Association. Published by Elsevier Inc. All rights reserved.
dc.subject.meshChronic Disease
dc.subject.meshInflammatory Bowel Diseases
dc.subject.meshPain
dc.subject.meshPatient Reported Outcome Measures
dc.titleInterpreting Patient-Reported Outcome Scores: Pediatric Inflammatory Bowel Disease as a Use Case
dspace.entity.typePublication
relation.isStudyOfPublication2e39cb9c-af89-478b-9397-93f0367c2acf
relation.isStudyOfPublication.latestForDiscovery2e39cb9c-af89-478b-9397-93f0367c2acf

Files